SIR 2026 Practice Guidance Updates PAE Recommendations for BPH

SIR's 2026 guidance on prostatic artery embolization (PAE) for benign prostatic hyperplasia updates patient selection, technique, and periprocedural care, reflecting RCT and meta-analysis data through 2025 and PAE's new AUA guideline recognition.

• Guideline document by SIR-appointed IR writing group synthesizing RCTs, meta-analyses, and retrospective studies published through 2025; updates the 2019 SIR multisociety consensus position statement.
• PAE now formally included in American Urological Association BPH guidelines as a viable alternative to transurethral resection of the prostate (TURP) — a significant shift in multidisciplinary acceptance.
• Specific outcome metrics and safety thresholds are addressed, but granular numbers (e.g., IPSS improvement figures or complication rates) are not reported in the source abstract.

RadPigeon summaries are original and for information only. They are not clinical advice.